The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

QUOTES-U.S. backs giving poorer countries access to COVID-19 vaccine patents, reversing stance

Thu, 06th May 2021 10:30

(Adds material)

May 6 (Reuters) - U.S. President Joe Biden on Wednesday
supported waiving intellectual property rights for COVID-19
vaccines, bowing to mounting pressure from Democratic lawmakers
and more than 100 other countries, but angering pharmaceutical
companies.

Following are reactions to the latest developments.

GAVI, THE GLOBAL VACCINE ALLIANCE

"We recognise also the significance of the (Biden)
administration’s commitment to work towards increasing raw
material production which will have an immediate impact on
alleviating current global supply constraints.

"Gavi urges now that in the interests of global equitable
access the US supports manufacturers to transfer not only IP but
also know-how in a bid to urgently boost global production."

THE INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS
& ASSOCIATIONS (IFPMA)

"Waiving patents of COVID-19 vaccines will not increase
production nor provide practical solutions needed to battle this
global health crisis. On the contrary, it is likely to lead to
disruption.

"The only way to ensure quick scaling up of and equitable
vaccine access to all those in need remains pragmatic and
constructive dialogue with the private sector."

SOUTH AFRICAN GOVERNMENT

"President (Cyril) Ramaphosa welcomes the position adopted
by the United States as an important reinforcement of a campaign
led by South Africa and India on behalf of emerging economies
that face vaccine shortages and production challenges.

"The anticipated temporary waiver provides a global response
to COVID-19. The proposal establishes a global solution to
enhance manufacturing and boost supply capacity, and enables
coordination and access to information currently under patent
protection.

"For countries that do not currently have manufacturing
capacity on certain medical technologies, the waiver could open
up more supply options and avoid countries being reliant on only
one or two suppliers. Where supply capacity currently exists, it
can be repurposed to COVID vaccine production and in this way
improve the supply available to all nations."

AUSTRALIAN TRADE MINISTER DAN TEHAN

"We welcome this positive development and look forward to
working with the U.S. and others to find solutions that boost
the global rollout of COVID-19 vaccines.

"Close collaboration between governments and vaccine
manufacturers will remain vital."

NEW ZEALAND TRADE MINISTER DAMIEN O'CONNOR

"New Zealand supports the waiver of IP protections on
vaccines as an important part of our collective efforts to
address the human catastrophe of the pandemic.

"We are also working in APEC, the WTO and other fora to
address other elements of vaccine supply issues including
through the supply chains that are limiting the availability of
vaccines regionally and globally."

ITALIAN MINISTRY OF HEALTH ROBERTO SPERANZA

"Biden's breakthrough on free access to vaccine patents for
all is an important step forward. Europe must also play its
part. This pandemic has taught us that we can only win
together."

DOCTORS WITHOUT BORDERS

"It is crucial that the waiver not just apply to
preventative vaccines, but it should also cover other medical
tools for COVID-19, including treatments for people who fall ill
and diagnostics to help curb the spread, as originally proposed
seven months ago.

"While this decision means other manufacturers will have the
information they need from pharmaceutical corporations - and the
legal permission - to help scale up global supply and get more
shots into the arms of people everywhere, this won't happen
immediately.

"For the remaining countries that continue to oppose the WTO
waiver..., they must drop their objections and put people’s
health before pharmaceutical profits, and waive IP on all
COVID-19 medical tools, including vaccines."

OXFAM HEALTH POLICY MANAGER ANNA MARRIOTT

“In this moment of crisis, we applaud the decision of
President Biden and his administration to pursue a new path that
prioritizes public health over private profits.

"This is a testament to the widespread public movement
calling for an end to vaccine monopolies.

“We are at a crucial point in the fight against coronavirus,
yet we have remained essentially at the mercy of a handful of
giant pharmaceutical corporations that have monopoly control
over the life-saving technologies we all need. The UK shouldn't
be left standing on the wrong side of history and must join the
U.S. in doing the right thing for humanity.

“We will now look to the White House for leadership in a
strong WTO outcome, in urgently insisting on the transfer of
technologies through the World Health Organization COVID-19
Technology Access pool, and in investing strategically to build
up regional vaccine hubs to defeat this and future pandemics."

GORDON BROWN, U.N. GLOBAL AMBASSADOR AND FORMER BRITISH
PRIME MINISTER

"I welcome the American decision on temporary patent waiver
which makes the COVID-19 vaccine accessible. Now we must make
the vaccine affordable. No one is safe until everyone is safe
and on June 11, at the G7 meeting, the richest countries should
make the momentous decision to pay two thirds of the $60 billion
cost of vaccinating the world."
(Reporting by Reuters staff; Editing by Nick Macfie and Mark
Heinrich)

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.